Chugai Pharmaceutical Co. Ltd.

5 trials 2 recruiting Commercial sponsor

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

3 Completed trials

14 Countries active

8 Unique IMPs

100% Results reported

Phase II

Phase I

Phase I (Other)

Phase II: 1 Phase I: 1 Phase I (Other): 3

Oversight events:

1 temporary halt 1 urgent safety measure across 2 trials

View oversight register →

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Antiphospholipid syndrome 2 Immune-mediated myositis 2 Dermatomyositis 2 Pemphigoid 2 Behcet's syndrome 2 Endometriosis 1 Neoplasm malignant 1

Top IMPs

AMY109 1 DESOGESTREL 1

All trials

5 total

Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-… Recruiting

2024-511346-39-00 Phase I (Other) 14 countries
Phase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) Recruiting

2023-507692-21-00 Phase I (Other) 14 countries
A study to evaluate the efficacy and safety of AMY109 in women with endometriosis Ended

2023-507289-14-00 Phase II 3 countries AMY109; DESOGESTREL
A Phase I study of STA551 and STA551 in combination with atezolizumab in patients with solid tumours Ended

2023-508764-30-00 Phase I 3 countries
A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE ASCENDING, SINGLE-DOSE STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC… Ended

2024-515151-38-00 Phase I (Other) 1 country

Showing 1–5 of 5 trials

← All sponsors A–Z